|
MechanismSARS-CoV-2 antigen inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot ApplicableIIT Comparison of safety and immunogenicity of FAKHRAVAC and Sinopharm booster doses for adults 18 years of age and older, fully vaccinated by Sinopharm: a ?parallel ??2?? arms, ?randomised, double blind clinical trial
Comparison of the safety and efficacy of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomized, non-inferiority clinical trial
Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial
100 Clinical Results associated with Organization of Defensive Innovation & Research
0 Patents (Medical) associated with Organization of Defensive Innovation & Research
100 Deals associated with Organization of Defensive Innovation & Research
100 Translational Medicine associated with Organization of Defensive Innovation & Research